Novel superparamagnetic iron oxide nanoparticles (SPIONs)
of Methotrexate
(MTX) were developed using supercritical liquid technology and optimized
with a Box–Behnken design in order to assess its potential
as a candidate for the treatment of breast cancer. MTX-SPIONs coated
with poly(lactic-co-glycolic acid)–polyethylene
glycol 400 had an aggregate size of 500 nm and an encapsulation efficiency
of 46.8 ± 3.9%. The Fourier-transformed infrared spectroscopy
analysis revealed a shift in the main bands due to intermolecular
hydrogen bonds, whereas the differential scanning calorimetry analysis
revealed the absence of the MTX melting endotherm, indicating complete
encapsulation with oxide nanoparticles. The zeta potential results
indicated a value of 4.98 mV, whereas the in vitro release study revealed
an initial burst release followed by a considerable release of 35.1
± 2.78% after 12 h. Using flow cytometry, control, MTX, and MTX-SPIONs
were evaluated for apoptosis, with MTX-SPIONs exhibiting greater apoptosis
than the control group and MTX. In addition, MTX-SPIONs inhibited
cell division and content organization while substantially increasing
the proportion of cells in the G1 and G2 phases relative to the control
group. MTX-SPIONs exhibited prolonged anticancer effects against MCF-7
cell lines compared to MTX alone, indicating that SPION-delivered
chemotherapeutics may increase cytotoxicity. The medication was stable
with low encapsulated drug loss, suggesting that the supercritical
liquid technology-based method is a promising way for generating drug–polymer
magnetic composite nanoparticles for cancer treatment.